Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-beta with a combination of imatinib mesylate and ACE inhibitor in rats.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  International Journal of Molecular Medicine

• Publication date

  2006-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.3892/IJMM.17.5.899PMID 16596278
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct–ligated rats

  2005cited by this paper
• Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451.

  2005cited by this paper
• Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats.

  2005cited by this paper
• Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice.

  2005cited by this paper
• Dominant-negative soluble PDGF-β receptor inhibits hepatic stellate cell activation and attenuates liver fibrosis

  2004cited by this paper
• Antisense strategy against PDGF B-chain proves effective in preventing experimental liver fibrogenesis.

  2004cited by this paper
• Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II.

  2003cited by this paper
• Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese.

  2003cited by this paper
• Liver fibrosis -- from bench to bedside.

  2003cited by this paper
• Vascular endothelial growth factor and receptor interaction is a prerequisite for murine hepatic fibrogenesis

  2003cited by this paper
• Angiotensin-II induces the tissue inhibitor of metalloproteinases-1 through the protein kinase-C signaling pathway in rat liver fibrosis development.

  2003cited by this paper
• The Myofibroblastic Conversion of Peribiliary Fibrogenic Cells Distinct from Hepatic Stellate Cells Is Stimulated by Platelet-Derived Growth Factor During Liver Fibrogenesis

  2003cited by this paper
• STI-571 inhibits in vitro angiogenesis.

  2003cited by this paper
• Adenoviral delivery of an antisense RNA complementary to the 3' coding sequence of transforming growth factor-beta1 inhibits fibrogenic activities of hepatic stellate cells.

  2002cited by this paper
• Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma

  2002cited by this paper
• Tissue inhibitor of metalloproteinases‐1 attenuates spontaneous liver fibrosis resolution in the transgenic mouse

  2002cited by this paper
• Current Strategies for Chemoprevention of Hepatocellular Carcinoma

  2002cited by this paper
• The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor.

  2001cited by this paper
• Inhibition of transforming growth factor β prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine-treated rats

  2001cited by this paper
• Hepatic Stellate Cell Proliferation is an Early Platelet-Derived Growth Factor-Mediated Cellular Event in Rat Cholestatic Liver Injury

  2001cited by this paper
• Cytokine Receptors and Signaling in Hepatic Stellate Cells

  2001cited by this paper
• Angiotensin‐II type 1 receptor interaction is a major regulator for liver fibrosis development in rats

  2001cited by this paper
• Pericytes: Cell Biology and Pathology

  2001cited by this paper
• Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.

  2000cited by this paper
• Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.

  2000cited by this paper
• Angiogenesis in cancer and other diseases

  2000cited by this paper
• Tissue inhibitor of metalloproteinases‐1 promotes liver fibrosis development in a transgenic mouse model

  2000cited by this paper
• Angiotensin II induces contraction and proliferation of human hepatic stellate cells.

  2000cited by this paper
• Fibrosis and angiogenesis.

  2000cited by this paper
• Mechanisms of angiogenesis and arteriogenesis

  2000cited by this paper
• Inhibition of transforming growth factor β prevents progression of liver fibrosis and enhances hepatocyte regeneration in dimethylnitrosamine‐treated rats

  2000cited by this paper
• In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis.

  1999cited by this paper
• Cytokines and Fibrogenesis

  1999cited by this paper
• Tissue inhibitors of metalloproteinases, hepatic stellate cells and liver fibrosis

  1998cited by this paper
• Molecular regulation of hepatic fibrogenesis.

  1998cited by this paper
• Fibrosis accelerates the development of enzyme‐altered lesions in the rat liver

  1998cited by this paper
• CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins.

  1997cited by this paper
• Tissue inhibitors of metalloproteinases in liver fibrosis.

  1997cited by this paper
• Biological functions of angiotensin and its receptors.

  1997cited by this paper
• Induction of beta-platelet-derived growth factor receptor in rat hepatic lipocytes during cellular activation in vivo and in culture.

  1994cited by this paper

• Roles of PDGF/PDGFR signaling in various organs

  2024cites this paper
• Nanotechnology-based combinational strategies toward the regulation of myofibroblasts and diseased microenvironment in liver fibrosis and hepatic carcinoma

  2023cites this paper
• Lenvatinib prevents liver fibrosis by inhibiting hepatic stellate cell activation and sinusoidal capillarization in experimental liver fibrosis

  2021cites this paper
• RUNX1 regulates SMAD1 by transcriptionally activating the expression of USP9X, regulating the activation of hepatic stellate cells and liver fibrosis.

  2021cites this paper
• Cirrhotic portal hypertension: From pathophysiology to novel therapeutics

  2020cites this paper
• Effects of Combined Admistration of Imatinib and Sorafenib in a Murine Model of Liver Fibrosis

  2020cites this paper
• Predictive Value of Precision-Cut Kidney Slices as an Ex Vivo Screening Platform for Therapeutics in Human Renal Fibrosis

  2020cites this paper
• World Journal of Gastroenterology From to of via the gut-liver-brain axis in

  2020cites this paper
• Role of hepatic stellate cell (HSC)-derived cytokines in hepatic inflammation and immunity.

  2019cites this paper
• Protective effects of combined Losartan and Nilotinib on carbon tetrachloride (CCl4)-induced liver fibrosis in rats

  2018cites this paper
• New Concepts on Reversibility and Targeting of Liver Fibrosis; A Review Article

  2018cites this paper
• Influence of amygdalin on PDG, IGF and PDGFR expression in HSC-T6 cells

  2018cites this paper
• Sorafenib and praziquantel synergistically attenuate Schistosoma japonicum-induced liver fibrosis in mice

  2018cites this paper
• Management strategies for liver fibrosis.

  2017cites this paper
• New Insight into the Anti-liver Fibrosis Effect of Multitargeted Tyrosine Kinase Inhibitors: From Molecular Target to Clinical Trials

  2016cites this paper
• Co-delivery of small molecule hedgehog inhibitor and miRNA for treating liver fibrosis.

  2016cites this paper
• Reversal of Cirrhosis

  2015cites this paper
• The Effect of Antifibrotic Drugs in Rat Precision-Cut Fibrotic Liver Slices

  2014cites this paper
• Precision-cut liver slices: an ex vivo model for the early onset and end-stage of liver fibrosis

  2014influential citation
• Therapeutic potential of targeting the renin angiotensin system in portal hypertension.

  2013cites this paper
• the Clinical Course of Chronic Myeloid Leukaemia Angiotensin System (RAS) Activity during - Effects of Imatinib Mesylate on Renin

  2013cites this paper
• Anti‐fibrotic activity and enhanced interleukin‐6 production by hepatic stellate cells in response to imatinib mesylate

  2012cites this paper
• Imatinib Mesylate Improves Liver Regeneration and Attenuates Liver Fibrogenesis in CCL4-Treated Mice

  2012cites this paper
• Possible involvement of angiogenesis in chronic liver diseases: interaction among renin-angiotensin-aldosterone system, insulin resistance and oxidative stress.

  2012cites this paper
• Transcriptome Analysis of the Effects of Gomisin A on the Recovery of Carbon Tetrachloride-Induced Damage in Rat Liver

  2011cites this paper
• Evidence for the involvement of TGF-β1-CTGF axis in liver fibrogenesis secondary to hepatic viral infection.

  2011cites this paper
• Prevention and treatment of Schistosoma mansoni-induced liver fibrosis in mice

  2011cites this paper
• Nilotinib counteracts thioacetamide‐induced hepatic oxidative stress and attenuates liver fibrosis progression

  2011cites this paper
• Comparison of imatinib, nilotinib and silymarin in the treatment of carbon tetrachloride-induced hepatic oxidative stress, injury and fibrosis.

  2011cites this paper
• Current status of novel antifibrotic therapies in patients with chronic liver disease

  2011cites this paper
• Antifibrosis: To Reverse the Irreversible

  2010cites this paper
• Role of angiotensin II in liver fibrosis‐induced portal hypertension and therapeutic implications

  2010cites this paper
• Investigación de nuevas estrategias terapeúticas para la inflamación y la fibrosis hepática.

  2010cites this paper
• Chronic intake of a high-cholesterol diet resulted in hepatic steatosis, focal nodular hyperplasia and fibrosis in non-obese mice

  2009cites this paper
• Effects of Imatinib Mesylate on Renin–Angiotensin System (RAS) Activity during the Clinical Course of Chronic Myeloid Leukaemia

  2009cites this paper
• Alcohol and liver fibrosis.

  2009cites this paper
• The key role of stem cell factor/KIT signaling in the proliferation of blast cells from Down syndrome-related leukemia

  2009cites this paper
• Therapeutic targeting of the PDGF and TGF-β-signaling pathways in hepatic stellate cells by PTK787/ZK22258

  2009cites this paper
• Hepatic stellate cells and liver fibrosis.

  2009cites this paper
• Alcohol and Liver Fibrosis

  2009cites this paper
• Advances in antifibrotic therapy

  2008cites this paper
• Platelet‐derived growth factor may be associated with fibrosis in a Down syndrome patient with transient myeloproliferative disorder

  2008cites this paper
• Potential of imatinib mesylate as a novel treatment for pulmonary fibrosis

  2008cites this paper
• Cytokines and renin-angiotensin system signaling in hepatic fibrosis.

  2008cites this paper
• Complexity in Interpretation of Embryonic Epithelial-Mesenchymal Transition in Response to Transforming Growth Factor-β Signaling

  2007cites this paper
• Combination Therapies for Choroidal Neovascularization

  2007cites this paper
• Effects of the Protein Kinase Inhibitor, Imatinib Mesylate, on Epithelial/Mesenchymal Phenotypes: Implications for Treatment of Fibrotic Diseases

  2007cites this paper
• Immunopathogenesis of hepatitis C virus infection and hepatic fibrosis: New insights into antifibrotic therapy in chronic hepatitis C

  2007cites this paper
• Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1–7) levels in experimental biliary fibrosis☆

  2007cites this paper
• Local inhibition of liver fi brosis by specifi c delivery of a PDGF kinase inhibitor to hepatic stellate cells

  2006cites this paper
• A potential strategy to treat liver fibrosis

  2006cites this paper